Effectiveness of Moxibustion Combined with Conventional Treatment for Moderate-Severe Persistent Allergic Rhinitis: Protocol for a Randomized, Controlled Trial
Journal Title: UNKNOWN - Year 2017, Vol 7, Issue 5
Abstract
Introduction: The incidence of allergic rhinitis (AR) has risen dramatically in recent years, and presents with higher symptom frequency, affecting quality of life. Clinical research shows that conventional medical treatment can rapidly relieve AR symptoms; however, there is a high incidence of relapse. Moxibustion treatment reportedly has a good effect in reducing the relapse rate. However, trial-based evidence for the effectiveness of these combined treatments is necessary. Methods and analysis: This is a protocol for a randomized, controlled trial comparing the effects of combined moxibustion and conventional treatment with conventional treatment alone for patients with moderate-severe persistent AR. After intervention, both groups will be followed-up for 3 months. The primary outcome is frequency of AR symptoms, which will be obtained via a self-recorded AR diary. The secondary outcomes include the Rhinoconjunctivitis Quality of Life Questionnaire score and use of daily medication. Ethics and dissemination: Ethical approval for the study has been granted by the Institutional Review Board of Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine (ECPJ-BDY-2016-16). Written informed consent will be obtained from all participants. The study findings will be published in open access peer-reviewed journals. Strengths and limitations of this study ▪ The trial is designed to address the gap in evidence regarding the effects of combined moxibustion and conventional treatment for patients with moderate-severe persistent AR. ▪ Experiences with moxibustion treatment in reducing the relapse rate of AR patients will be examined. ▪ The findings may provide the inter-complementary programme for patients with moderate-severe persistent AR. ▪ Although numerous of outcomes are assessed, even including some original parts, there may exist different perspectives on what the most suitable outcomes are. ▪ This RCT is an exploratory study with limited experience. Therefore, there are significant improvements still to be made in the sample size and follow-up pattern.
Authors and Affiliations
Sheng-Nan Guo, Xue-Si Hou, Zhi-Hong Wen, Yi-Fan Jia, Shu-Han Qu, Wei-Mei Zeng, Yi Xiao, Federicox Marmori, Dong-Mei Li, Ji-Ping Zhao
Keywords
Related Articles
- EP ID EP387119
- DOI 10.4172/2167-0870.1000328
- Views 59
- Downloads 0
Feasibility Study of Bolus 5-Fluorouracil+L-Leucovorin as Salvage Line Chemotherapy for Oral Fluorouracil-Resistant Unresectable Gastric Cancer: Hokkaido Gastrointestinal Cancer Study Group Study HGCSG1502
In November 2015 we began a feasibility study of salvage line chemotherapy with 5-fluorouracil and l-leucovorin given in an intravenous bolus once weekly followed by a 2-week rest period within a 8-week cycle in patients...
Editor’s Note: Journal of Clinical Trials
In clinical research, several studies use to perform on human subjects to evaluate the dependence of the disease occurrence with one or more parameters. Such studies are called 'Clinical trials', which are having great i...
Safety and Efficacy of Intracoronary Ad-HGF Administration for Treating Severe Coronary Disease: Results From Long-Term Follow-Up of a Phase I Clinical Trial
Objective: This study is a long-term follow-up of our previous phase I clinical trial and aims at evaluating the long-term safety and efficacy of intracoronary Ad-HGF administration for treating coronary disease. Method...
Management of Pleural Effusion by Combining Talc Poudrage and Indwelling Pleural Catheter: A Retrospective Single Center Study
Objective: In 2013 we started to combine VATS poudrage with simultaneous insertion of an indwelling pleural catheter (IPC) for management of malignant pleural effusions (MPE) to achieve successful pleurodesis, avoid recu...
Neurofibromatosis Type 1 and Recurrent Metastatic Low-Grade Fibromyxoid Sarcoma: Case Report about a Rare Association
Neurofibromatosis type 1 is the most frequent phacomytosis. Patients with neurofibromatosis type 1 (NF1) have a high risk to develop benign or malignant tumors of neurogenic or non-neurogenic origin. The association of (...